Hepatoid adenocarcinoma of the stomach: A case report and review of the literature

Introduction

Hepatoid adenocarcinoma of the stomach (HAS) is a particular type of extrahepatic adenocarcinoma, presenting with morphological characteristics identical to those of hepatocellular carcinoma (HCC). A case of α-fetoprotein-producing gastric adenocarcinoma was reported by Ishikura et al (1) in 1985. The authors suggested the name of HAS due to the ability of the tumor cells to produce α-fetoprotein (AFP), which is characteristic of hepatoid adenocarcinoma cells (1). HAS is reported to occur with more frequent lymph node and liver metastasis and exhibits a poorer prognosis than common gastric cancer (CGC) (2). HAS is rare (with a worldwide incidence of 0.3–1%) of all kinds of gastric cancer (2–4), the sypmtoms are similar to those of normal gastric cancer (abdominal discomfort, fullness of anorexia, epigastric pain, voimiting and weight loss), surgery is the usual treatment option (4–7). The literature review presented in this study was conducted to contribute towards the improvement of the diagnosis and treatment of HAS (3). We report a case of a 72-year-old female patient who sufferd upper abdominal discomfort. Endoscopical and radiological examination revealed a neoplasm in the stomach, however serum α-fetoprotein levels were normal. Written informed consent was obtained from the patient's family.

Case report

Case presentation

A 72-year-old Chinese female presented to Huashan Hospital (Shanghai, China) complaining of upper abdominal discomfort for the previous two months. The patient was admitted to the General Surgery Department of Huashan Hospital on October 8th, 2011. The results of the physical examinations were unremarkable. The past medical history revealed nothing significant; the patient had not previously undergone any surgery and there was no family history of cancer. The laboratory investigation revealed normal blood levels following routine tests, and liver and kidney function were normal. The white blood cell count was 6.8×109/l (normal range, 4.5–11×109/l), the hematocrit level was 120 g/l (normal range, 110–150 g/l), the red blood cell count was 3.93×1012/l (normal range, 3.5–5.0×1012/l), alanine aminotransferase levels were 11 U/l (normal range, 0–50 U/l), aspartate aminotransferase level was 18 U/l (normal range, 0–30 U/l), the bilirubin level was 12 µmol/l (normal range, 3.4–20.4 µmol/l), the serum creatinine level was 87 µmol/l (normal range, 50–130 µmol/l) and the blood urea nitrogen level was 5.3 mmol/l (normal range, 2.5–7.0 mmol/l) In addition, the AFP level was 4.93 µg/l (normal value, <10 µg/l), carcinoembryonic antigen (CEA) level 0.69 µg/l (normal range, 0–10 µg/l), a CA125 level of 30.55 U/ml (normal range, 0–35 U/ml) and the CA724 levels of 2.5 U/ml (normal range, 0–8.2 U/ml), were all within the normal ranges. Furthermore, the hepatitis B and C panels were negative. A gastroduodenoscopy revealed a large gastric antrum ulcer and, subsequently, irregular and hyperchromatic nuclei were observed in the carcinoma cells, which was diagnosed as a poorly differentiated adenocarcinoma. Computed tomography was performed and mural thickening of the gastric antrum was observed, as well as a gastric mass, measuring 10×5 cm in diameter. In addition, massive lymph node swelling around the greater and lesser curvature of the stomach, head of pancreas, portal and splenic vein was evident.

Treatment

The patient underwent a distal gastrectomy plus resection of the small intestine with tumor debulking and subsequent chemotherapy (150 mg oxaliplatin with 3.5 g fluorouracil and 300 mg folinic acid, six cycles). For the first two years after surgery, the patient was followed-up every three-four months, then every six months thereafter. The patient was without relapse at the time of writing.

Pathological analysis

The pathological analysis was conducted on the resected specimen, which consisted of stomach tissue, measuring 22 cm in the greater gastric curvature and 15 cm in the lesser curvature. The serosal surface showed an ill-defined, hemorrhagic, necrotic mass, measuring 10.5×6×1.5 cm, which invaded into the whole gastric wall. Sectioning of the mass revealed a gray-white, homogeneous cut surface with scattered areas of hemorrhage and necrosis. Sections of the mass exhibited malignant cells arranged in a solid to trabecular pattern (Fig. 1A). The cells were polygonal shaped with well-defined cytoplasmic borders. The cytoplasm was clear to eosinophilic and a number of the cells exhibited centrally located hyperchromatic nuclei. Immunohistochemical analysis was performed to further characterize the tumor. The tumor cells were immunohistochemically positive for Hep1 (Fig. 1B), CK, CK8 (Fig. 1C), CK18 (Fig. 1D), P53 and Ki67 (50%+), and negative for Vim, LCA, ChroA, Syn and CerbB-2.

Figure 1. (A) Hematoxylin and eosin staining (magnification, x100). Cancer cells were polygonal, with an abundant eosinophilic cytoplasm, the nuclei were centered, large and irregular and the nucleolus was clearly visible. Positive staining was observed for (B) Hep1, (C) CK8 and (D) CK18 (magnification, x400).

Discussion

HAS originates from gastric mucosa, exhibiting morphological features of CGC and hepatoid adenocarcinoma, and has been classified as a rare subtype of gastric malignant tumors (4). According to recent studies, the incidence among gastric cancer cases was 1.5–15% (5,6). The mean incidence age of HAS has been reported to be 63.5 years of age and more male patients have been observed, with a male to female ratio of 2.3:1 (7). The most common tumor site was identified to be the gastric antrum (7). The diagnosis of HAS is dependent on the pathological examination.

The formation of HAS may be regarded as consequence of embryogenesis, as the stomach and liver are derived from the foregut three to four months following fertilization. Gastric adenocarcinoma cells may be misdirected during differentiation and alternatively oriented towards hepatoid cells, the most characteristic of which are AFP-producing (8). AFP produced by HAS can be distinguished from AFP-producing gastric cancer (AFPPGC), another distinctive type of gastric cancer, as it exhibits a higher canavalin binding rate than that of AFPPGC (>90 vs. <50%) (9). In a study by Ooi et al, the difference in canavalin binding was hypothesized to be due to the various origin cells of AFP. In AFPPGC, AFP was secreted by gastric adenocarcinoma cells, while it was secreted by hepatoid cells in cases of HAS (10).

As a rare subtype of gastric malignant tumors, HAS has been reported in individual cases from various therapeutic centers (1,3,5,6,9). The elevated serum AFP level is regarded as a significant feature of HAS (11) and, among the previously reported HAS patients, 84.8% were observed to have elevated AFP levels ranging from 10–475000 ng/ml (12).

In a number of previously reported cases, the pathological features of HAS were as follows: i) HAS cells were large and polygonal with prominent nucleoli and abundant cytoplasm. The polygonal tumor cells were eosinophilous under hematoxylin and eosin staining, forming myeloid or cord structures, separated by sinusoidal capillaries (3,14); ii) trabecular and intestinal-like structures may be identified in HAS cells and were defined as two pathological subtypes (7,12,14). In these subtypes, hyaline particles may be observed, indicated by positive periodic acid-Schiff staining (3,13); iii) steatosis and biliation were identified in a number of HAS cells (11,12); iv) ultra microstructure of the HAS cells showed microvilli differentiation, originating from gastrointestinal epithelial cells (3,8,13); and v) characteristic immunohistochemical staining, as reported in the literature, consisted of positive AFP expression in the majority of HAC patients (91.6%) and positive CEA staining observed in 78.7% cases (1,10,14). Additionally, cells were commonly observed to be positive for α1-antitrypsin and α1-antichymotrysin following immunohistochemical analysis (13,14).

The clinical symptoms are not specific enough to accurately determine the diagnosis of HAS, as similar symptoms including nausea, loss of appetite and epigastric distress may be present in a variety of malignant tumors of the digestive system. Therefore, in gastric tumor cases with an elevated serum AFP level, the possibility of HAS must be considered. Preoperative computed tomography and β-ultrasound of the liver are routinely recommended for the exclusion of HCC, hepatic metastasis, teratoma and other diseases that may also produce AFP (4,5,7). Histologically, the hepatoid structure identified in the gastric adenocarcinoma region may contribute significantly to the diagnosis (3–5,7). Immunohistochemical analysis may exhibit positive staining for epithelial membrane antigen and CEA, which may aid in the exclusion of gastric metastasis of HCC (4,8,10,11). New molecular markers, including palate, lung, and nasal epithelium clone protein and GATA4, may allow the differentiation of gastric hepatoid adenocarcinoma, HCC and CGC (15,16).

Previous studies have reported that HAS frequently occurred with liver metastasis and exhibited a shorter interval between gastrectomy and liver metastasis than that of CGC, leading to a poorer prognosis (17,18). As reported by Liu et al, the one-, three- and five-year survival rates of HAS were 30, 13 and 9%, respectively, compared with 95, 57 and 38%, respectively in the CGC group (19). The poorer prognosis indicated a more aggressive biological behavior of HAS compared with that of CGC; the mechanism of this was proposed to be due to the immunosuppressive and protease-inhibitory properties, which may enhance the invasiveness of the tumor (20).

Due to the limited number of reported cases, there is currently a lack of understanding surrounding HAS. Therefore, further clinical studies and information are required for clinicians and pathologists to improve the diagnosis and treatment for this subtype of gastric cancer.

References